S. Jeson Sangaralingham

Author

Also Known As

Horng H. Chen, S J Sangaralingham, S Jeson Sangaralingham, S. J Sangaralingham, S. J. Sangaralingham, S. Jeson M. Sangaralingham, S. Jeson Sangaralingham, S. Sangaralingham, S.J. Sangaralingham, S. Jeson Sangaralingham

139

Publications

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Florida Mayo Clinic in Arizona University of Parma Mahindra and Mahindra Limited (India)

About

S. Jeson Sangaralingham is an author at Mayo Clinic specializing in medicine, cardiovascular disease, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	797
2	Public Health	3	3	174
3	Engineering	1	1	63
4	Health Sciences	1	1	59
5	Natural Sciences	1	1	24

S. Jeson Sangaralingham

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
The Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide S. Jeson Sangaralingham, Brenda K. Huntley, Fernando L. Martín, Hypertension	2010	127
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure Lindsey R. Sangaralingham, S. Jeson Sangaralingham, Nilay D. Shah, Circulation Heart Failure	2018	88
Circulating Aldosterone and Natriuretic Peptides in the General Community Alessia Buglioni, Valentina Cannone, Alessandro Cataliotti, Hypertension	2014	85
Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection Fernando L. Martín, Paul M. McKie, Alessandro Cataliotti, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology	2011	82
Natriuretic peptide pathways in heart failure: further therapeutic possibilities S. Jeson Sangaralingham, Michaela Kühn, Valentina Cannone, Cardiovascular Research CardiomyopathyHeart FailureCardiovascular DiseaseMedicinePeptide Engineering	2022	69
Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis Tomoko Ichiki, Guido Boerrigter, Brenda K. Huntley, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology Cardiac MuscleHeart FailureActive NpsDiastolic FunctionExperimental Heart Failure	2012	67
Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up Study Paul M. McKie, Alessandro Cataliotti, S. Jeson Sangaralingham, Mayo Clinic Proceedings Cardiovascular EpidemiologyCardiovascular DiseasePredictive UtilityGeneral CommunityCardiovascular Pharmacology	2011	64
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction Nicholas Y. Tan, Lindsey R. Sangaralingham, S. Jeson Sangaralingham, JACC Heart Failure Comparative EffectivenessHeart FailureCardiovascular DiseaseCardiovascular PharmacologyPharmacotherapy	2019	64
CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart Fernando L. Martín, S. Jeson Sangaralingham, Brenda K. Huntley, PLoS ONE Cardiac MuscleHeart FailureEngineeringPharmacotherapyBiomedical Engineering	2012	63
Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications Tomoko Ichiki, John A. Schirger, Brenda K. Huntley, Journal of Molecular and Cellular Cardiology Cardiac MuscleCardiomyopathyHeart FailureCardiovascular DiseaseCardiac Physiology	2014	59

Page 1